Bio-Rad and Myriad RBM Partner to Commercialize Multiplex Biomarker Kits for Life Science Research
Bio-Rad Laboratories, Inc. (NYSE: BIO) and Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics Inc. (NASDAQ: MYGN) today announced that they have partnered to develop and distribute high-quality immunoassay kits. Under the terms of the agreement, Myriad RBM grants Bio-Rad exclusive distribution rights, for research purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.